LYEL (Lyell Immunopharma) ROCE %: -58.59% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYEL Lyell Immunopharma Inc LYEL
55 GF Score
Price $13.19
GF Value $5.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Lyell Immunopharma ROCE %?

Lyell Immunopharma LYEL +1.47% 55 ROCE % is -58.59% as of Mar. 2026. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $5.26 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lyell Immunopharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -58.59%.

Lyell Immunopharma  (NAS:LYEL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lyell Immunopharma ROCE % Related Terms

Lyell Immunopharma ROCE % Historical Data

* Premium members only.

The historical data trend for Lyell Immunopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyell Immunopharma ROCE % Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -22.15 -18.88 -30.57 -38.22 -55.41

Lyell Immunopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.59 -49.60 -41.13 -73.57 -58.59
LYEL
55GF Score
Lyell Immunopharma Inc LYEL
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyell Immunopharma ROCE % Calculation

Lyell Immunopharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-201.629/( ( (490.859 - 53.788) + (340.052 - 49.412) )/ 2 )
=-201.629/( (437.071+290.64)/ 2 )
=-201.629/363.8555
=-55.41 %

Lyell Immunopharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-177.044/( ( (340.052 - 49.412) + (350.626 - 36.947) )/ 2 )
=-177.044/( ( 290.64 + 313.679 )/ 2 )
=-177.044/302.1595
=-58.59 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -58.59% mean?
Lyell Immunopharma (LYEL) has a ROCE % of -58.59% as of Mar. 2026.
Is Lyell Immunopharma's ROCE % too high?
Lyell Immunopharma's current ROCE % is -58.59%. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's ROCE % compare to ALXO and ARMP?
Lyell Immunopharma's ROCE % of -58.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lyell Immunopharma's current ROCE % is -58.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current ROCE % is -58.59%. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current ROCE % is -58.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyell Immunopharma (LYEL) Overvalued in 2026?

Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued. The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26. GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.

Key valuation signals for LYEL:

  • ROCE %: -58.59%
  • GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyell Immunopharma Business Description

Address 201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score

Get the complete analysis for LYEL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.19
Price
$5.26
GF Value